Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

By W. Busse, J. Corren, B. Lanier, M. McAlary, A. FowlerTaylor, G. Cioppa, A. As, N. Gupta. Journal of Allergy and Clinical Immunology, 2001

1,276 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? (2006, neutral): “7 There were 215 individual references in the relevant chapter of the GINA guidelines from which 17 qualifying RCTs were identified and included in the analysis (Figure 2).(13-29) The characteristics of the included RCTs are given in Table 2.”
Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (2007, positive): “The development of monoclonal antibodies against IgE has shown that the reduction of IgE is effective in asthma treatment (Busse et al. 2001; Holgate et al. 2005).”
Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. (2010, background): “, those requiring systemic corticosteroids or doubling of ICS dose) (16), the percentage of subjects experiencing severe exacerbations, respiratory-related unscheduled physician office visits, emergency department (ED) visits, hospitalizations, and days missed from work/school or other activities du”